Q BIOMED INC. (QBIO) Financials
Newest figures come from the 10-Q for Q1 FY2023, filed Jun 23, 2023. Each column of the statement tables below links to the filing it was taken from.
Q BIOMED INC. (QBIO) reported $284K in revenue for fiscal year 2022, up 45.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Q BioMed’s dominant mechanic is a tiny, improving revenue base operating against a balance sheet funded by liabilities and dilution.
FY2022 combined a net loss of-$2.1M with operating cash flow of$1.9M , so reported cash generation diverged sharply from accounting earnings. However, investing cash flow was-$3.1M while financing cash flow added only$908K ; the operating inflow therefore did not translate into positive overall reported cash flow.
Gross margin improved materially, moving from
FY2022 current assets were only
Financial Health Signals
Q BIOMED INC. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Q BIOMED INC. scores -32.23, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($15K) relative to total liabilities ($8.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Q BIOMED INC. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 3 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Q BIOMED INC. reported a net loss of $2.1M while generating $1.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Q BIOMED INC. reported an operating loss of $3.4M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Q BIOMED INC. reported -$722K in net income in Q1 2023. This represents an increase of 68.5% from the same quarter a year earlier. Against the prior quarter it is down 131.3%.
Q BIOMED INC. earned -$0.02 per diluted share (EPS) in Q1 2023. Against the prior quarter it is down 125.0%.
Not reported for Q1 2023.
Not reported for Q1 2023.
Cash & Balance Sheet
Q BIOMED INC. held $50K in cash as of Q1 2023; long-term debt is not reported for that period.
Not reported for Q1 2023.
Not reported for Q1 2023.
Margins & Returns
None of these metrics is reported for Q1 2023.
Capital Allocation
Q BIOMED INC. invested $3K in research and development in Q1 2023. This represents a decrease of 96.1% from the same quarter a year earlier. Against the prior quarter it is down 87.9%.
Not reported for Q1 2023.
Not reported for Q1 2023.
QBIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $13K | $26K-42.5% | $170K+278.9% | $75K | N/A | $46K+204.5% | $45K+200.0% |
| Cost of Revenue | $3K-96.6% | $80K | $66K-9.9% | $73K+56.8% | $74K+82.2% | N/A | $74K-53.5% | $46K+33.7% |
| Gross Profit | -$3K-324.4% | -$68K | -$40K-43.0% | $98K+7081.1% | $1K+102.7% | N/A | -$28K+80.4% | -$1K+92.9% |
| R&D Expenses | $3K-96.1% | $22K | $21K-89.7% | $13K-95.5% | $69K-60.1% | N/A | $202K-67.1% | $292K+1336.1% |
| SG&A Expenses | $440K-59.9% | $476K | $720K-47.5% | $1.0M-32.9% | $1.1M-48.7% | N/A | $1.4M-8.0% | $1.5M-4.9% |
| Operating Income | -$445K+61.8% | N/A | N/A | N/A | -$1.2M | N/A | N/A | N/A |
| Interest Expense | $277K-33.2% | $276K | $240K+141.0% | $454K+433.2% | $414K+726.7% | N/A | $99K+1001.6% | $85K+0.1% |
| Net Income | -$722K+68.5% | $2.3M | -$795K+55.5% | -$1.3M+33.4% | -$2.3M+7.5% | N/A | -$1.8M+20.8% | -$1.9M-2.5% |
| EPS (Basic) | -$0.02+75.0% | $0.08+200.0% | -$0.03+57.1% | -$0.06+25.0% | -$0.08+27.3% | -$0.08+46.7% | -$0.07+36.4% | -$0.08 |
| EPS (Diluted) | -$0.02 | $0.08 | -$0.03 | -$0.06+25.0% | -$0.08+27.3% | -$0.08+46.7% | -$0.07+36.4% | -$0.08 |
| Diluted Shares (Avg) | 109M | N/A | 45M | 33M+25.6% | 30M+20.1% | N/A | 28M+23.3% | 26M |
Not reported in any period shown, so not listed: EBITDA, Income Tax.
QBIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.5M+543.5% | $3.5M+334.3% | $498K-17.2% | $470K-40.1% | $538K-37.6% | $809K+29.8% | $602K-68.1% | $785K-78.4% |
| Current Assets | $34K-83.1% | $72K-84.3% | $186K-22.4% | $145K-64.6% | $201K-57.7% | $459K+105.6% | $239K-83.8% | $410K-87.2% |
| Cash & Equivalents | $50K-63.6% | $344K0.0% | $138K-8.9% | $27K-90.6% | $137K-68.5% | $344K+94.2% | $151K-88.6% | $290K-90.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | N/A | N/A | $23K | $22K | N/A | $22K | N/A | N/A |
| Accounts Receivable | $0-100.0% | $12K-85.6% | $12K-70.3% | $74K+79.5% | $28K | $80K | $39K+216.1% | $41K+260.0% |
| Long-Term Investments | $3.1M | $3.1M | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $9.9M+55.6% | $8.1M+48.0% | $7.7M+114.9% | $7.6M+154.0% | $6.4M+140.4% | $5.5M+223.4% | $3.6M+104.6% | $3.0M+96.4% |
| Current Liabilities | $9.9M+55.6% | $8.1M+48.0% | $7.7M+114.9% | $7.6M+154.0% | $6.4M+140.4% | $5.5M+223.4% | $3.6M+115.7% | $3.0M+96.4% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $0 |
| Total Equity | -$6.4M-10.5% | -$4.6M+1.5% | -$7.2M-141.4% | -$7.1M-223.5% | -$5.8M-226.4% | -$4.7M-335.7% | -$3.0M-2466.8% | -$2.2M-203.7% |
| Retained Earnings | -$68.3M-3.0% | -$66.1M-3.1% | -$68.4M-10.2% | -$67.6M-12.2% | -$66.3M-13.7% | -$64.1M-14.7% | -$62.1M-18.3% | -$60.3M-20.1% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
QBIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$138K+63.3% | $2.7M+271.0% | -$239K+71.5% | -$110K+89.9% | -$377K+53.9% | -$1.6M-6.0% | -$840K+50.4% | -$1.1M+35.1% |
| Stock-Based Compensation | $16K-89.4% | N/A | $22K | $261K | $152K-88.9% | N/A | N/A | N/A |
| Financing Cash Flow | $111K-34.5% | $388K-77.9% | $350K-50.1% | $0-100.0% | $170K-84.2% | $1.8M+442.7% | $701K | $940K-76.2% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
QBIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | -539.8% | -152.9% | 57.3%+60.4pp | 1.5% | N/A | -61.5% | -3.1% |
| Operating Margin | N/A | N/A | N/A | N/A | -1551.4% | N/A | N/A | N/A |
| Net Margin | N/A | 18368.3% | -3026.6% | -745.4% | -3049.1% | N/A | -3913.3% | -4240.6% |
| Return on Assets | -20.8%+404.2pp | 65.5% | -159.7%+137.5pp | -270.3%-27.2pp | -425.1%-138.1pp | N/A | -297.1%-177.4pp | -243.1%-191.8pp |
| Current Ratio | 0.000.0x | 0.01-0.1x | 0.020.0x | 0.02-0.1x | 0.03-0.1x | 0.080.0x | 0.07-0.8x | 0.14-2.0x |
| Asset Turnover | N/A | 0.00 | 0.050.0x | 0.36+0.3x | 0.14+0.1x | N/A | 0.08+0.1x | 0.06+0.1x |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$4.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Q BIOMED INC. QBIO | FY2022 | $284K | -$2.1M | N/A | $15K | — |
| SCOPUS BIOPHARMA INC SCPS | FY2022 | $0 | N/A | N/A | $13K | — |
| VIRPAX PHARMS INC VRPX | FY2024 | N/A | N/A | N/A | $5.7M | — |
| EVELO BIOSCIENCES INC EVLO | FY2022 | N/A | -$114.5M | N/A | $9K | — |
| PAXMEDICA INC PXMD | FY2023 | $0 | -$18.3M | N/A | $2.8M | — |
Where Q BIOMED INC. Ranks
Frequently Asked Questions
What is Q BIOMED INC.'s annual revenue?
Q BIOMED INC. (QBIO) reported $284K in total revenue for fiscal year 2022. This represents a 45.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Q BIOMED INC.'s revenue growing?
Q BIOMED INC. (QBIO) revenue grew by 45.4% year-over-year, from $196K to $284K in fiscal year 2022.
Is Q BIOMED INC. profitable?
No, Q BIOMED INC. (QBIO) reported a net income of -$2.1M in fiscal year 2022.
What is Q BIOMED INC.'s gross margin?
Q BIOMED INC. (QBIO) had a gross margin of -3.2% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.
What is Q BIOMED INC.'s operating cash flow?
Q BIOMED INC. (QBIO) generated $1.9M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.
What are Q BIOMED INC.'s total assets?
Q BIOMED INC. (QBIO) had $3.5M in total assets as of fiscal year 2022, including both current and long-term assets.
How much does Q BIOMED INC. spend on research and development?
Q BIOMED INC. (QBIO) invested $125K in research and development during fiscal year 2022.
What is Q BIOMED INC.'s current ratio?
Q BIOMED INC. (QBIO) had a current ratio of 0.01 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
What is Q BIOMED INC.'s return on assets (ROA)?
Q BIOMED INC. (QBIO) had a return on assets of -58.4% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
Why is Q BIOMED INC.'s debt-to-equity ratio negative or not reported?
Q BIOMED INC. (QBIO) has negative shareholder equity of -$4.6M as of fiscal year 2022, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Q BIOMED INC.'s Altman Z-Score?
Q BIOMED INC. (QBIO) has an Altman Z-Score of -32.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Q BIOMED INC.'s Piotroski F-Score?
Q BIOMED INC. (QBIO) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Q BIOMED INC.'s earnings high quality?
Q BIOMED INC. (QBIO) reported a net loss of $2.1M while generating $1.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Q BIOMED INC. cover its interest payments?
Q BIOMED INC. (QBIO) reported an operating loss of $3.4M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.